Aadi Bioscience, Inc. announced financial results for the third quarter ended September 30, 2024, and provided recent corporate progress. "The third quarter saw strong sales growth for FYARRO, backed by continued account momentum, increased demand...
Vensica Medical a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy...
BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral, once-daily ORLADEYO® (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...
Aileron Therapeutics, Inc. a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced the presentation of two abstracts...
Blue Earth Therapeutics Ltd, an emerging leader in the development of therapeutic radiopharmaceuticals, today announced further positive developments for its novel investigational radioligand therapies. Enrolment of patients in the Phase 1 trial...
Hansa Biopharma AB, announced positive results from a 12-month follow up analysis from the NICE-01 trial of HNSA-5487, the Company's next generation immunoglobulin G (IgG)-cleaving molecule, assessing IgG recovery, immunogenicity and redosing...
BioCare, a leader in specialty pharmaceutical distribution, is excited to announce its new partnership with AeroSafe Global, a pioneer in reliable, sustainable cold chain solutions. This collaboration introduces an innovative, reusable...
The ISCT Institute of Training & Development, a division of the International Society for Cell and Gene Therapy (ISCT), has become the first cell and gene therapy (CGT) organization to receive globally recognized accreditation from the ANSI...
Zhejiang Doer Biologics Co., Ltd. a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast...
Galmed Pharmaceuticals Ltd. a clinical-stage biopharmaceutical company for liver, metabolic and fibro-inflammatory diseases announced that the one-year results of the Open-Label part (ARCON ) of its global Phase 3 trial of Aramchol in 150 patients...
EydisBio, Inc. is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to EYD-001, its highly selective and potent, orally bioavailable TAK1 inhibitor for the treatment of systemic sclerosis....
Anixa Biosciences, Inc. a biotechnology company focused on the treatment and prevention of cancer, announced its strategic plan for a Phase 2 study for its breast cancer vaccine. The Phase 1 trial is being conducted at Cleveland Clinic, funded by...
Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, showcased robust growth in its raw materials business in its newly released 2024 mid-year financial report. The company reported a total revenue of RMB 2.811...
Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021(cilnidipine), a fourth-generation calcium channel antagonist. Aisa is...
Forge Biologics, a member of Ajinomoto Bio-Pharma Services and leading manufacturer of genetic medicines, today announced it will be the adeno-associated virus (AAV) development and manufacturing partner for the Muscular Dystrophy Association’s...
ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, announced the...
Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND")...
Corina Intrauterine Drug-Eluting System ("Corina"), developed by Yipurun (Shanghai) Biotechnology Co., Ltd. ("YPR"), has received approval in China (G.X.Z.Z. 20243181461) for use in patients with moderate-to-severe intrauterine adhesions (IUA) who...
